Abstract
The discovery of anandamide as an endogenous ligand for the cannabinoid receptors has led to a resurgence of interest in the fatty acid amides. However, N-palmitoylethanolamine (PEA), a shorter and fully saturated analogue of anandamide, has been known since the fifties. This endogenous compound is a member of the N-acylethanolamines, found in most mammalian tissues. PEA is accumulated during inflam-mation and has been demonstrated to have a number of anti-inflammatory effects, including beneficial effects in clinically relevant animal models of inflammatory pain. It is now engaged in phase II clinical development, and two studies regarding the treatment of chronic lumbosciatalgia and multiple sclerosis are in progress. However, its precise mechanism of action remains debated. In the present review, the biochemical and pharmacological properties of PEA are discussed, in particular with respect to its analgesic and anti-inflammatory properties.
Keywords: Palmitoylethanolamide, anandamide, cannabinoid, N-acylethanolamines, dicyclohexylcarbodiimide, N-palmitoylethanolamine, N-oleoylethanolamine, Tetrahydrocannabinol, Amide Hydrolase
Current Medicinal Chemistry
Title: The Palmitoylethanolamide Family: A New Class of Anti-Inflammatory Agents ?
Volume: 9 Issue: 6
Author(s): Didier M. Lambert, Severine Vandevoorde, Kent-Olov Jonsson and Christopher J. Fowler
Affiliation:
Keywords: Palmitoylethanolamide, anandamide, cannabinoid, N-acylethanolamines, dicyclohexylcarbodiimide, N-palmitoylethanolamine, N-oleoylethanolamine, Tetrahydrocannabinol, Amide Hydrolase
Abstract: The discovery of anandamide as an endogenous ligand for the cannabinoid receptors has led to a resurgence of interest in the fatty acid amides. However, N-palmitoylethanolamine (PEA), a shorter and fully saturated analogue of anandamide, has been known since the fifties. This endogenous compound is a member of the N-acylethanolamines, found in most mammalian tissues. PEA is accumulated during inflam-mation and has been demonstrated to have a number of anti-inflammatory effects, including beneficial effects in clinically relevant animal models of inflammatory pain. It is now engaged in phase II clinical development, and two studies regarding the treatment of chronic lumbosciatalgia and multiple sclerosis are in progress. However, its precise mechanism of action remains debated. In the present review, the biochemical and pharmacological properties of PEA are discussed, in particular with respect to its analgesic and anti-inflammatory properties.
Export Options
About this article
Cite this article as:
Lambert M. Didier, Vandevoorde Severine, Jonsson Kent-Olov and Fowler J. Christopher, The Palmitoylethanolamide Family: A New Class of Anti-Inflammatory Agents ?, Current Medicinal Chemistry 2002; 9 (6) . https://dx.doi.org/10.2174/0929867023370707
DOI https://dx.doi.org/10.2174/0929867023370707 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Higher Anti-angiogenesis Activity, Better Cellular Uptake and Longer Half-life of a Novel Glyco-modified Endostatin by Polysulfated Heparin
Current Pharmaceutical Biotechnology Rheumatoid Arthritis, Immunosenescence and the Hallmarks of Aging
Current Aging Science Fatty Acid-Mediated Inhibition of Metal Binding to the Multi-Metal Site on Serum Albumin: Implications for Cardiovascular Disease
Current Topics in Medicinal Chemistry Expression and Function of the Leukocyte Integrins in Medicine
Current Genomics Vitamins B1, B2, B3 and B9 – Occurrence, Biosynthesis Pathways and Functions in Human Nutrition
Mini-Reviews in Medicinal Chemistry CD14-Dependent Innate Immunity-Mediated Neuronal Damage in Vivo is Suppressed by NSAIDs and Ablation of a Prostaglandin E2 Receptor, EP2
Current Medicinal Chemistry - Central Nervous System Agents Conference Report: 182nd AAAS Annual Meeting, Washington DC, February 11-15, 2016
CNS & Neurological Disorders - Drug Targets Visible Light Assisted Hantzsch Reaction: Synthesis of Polycyclic Dihydropyridines
Letters in Organic Chemistry The Discovery of Epidepride and Its Analogs as High-Affinity Radioligands for Imaging Extrastriatal Dopamine D2 Receptors in Human Brain
Current Pharmaceutical Design Radionuclide Antibody-Conjugates, a Targeted Therapy Towards Cancer
Current Radiopharmaceuticals CSF as a Surrogate for Assessing CNS Exposure: An Industrial Perspective
Current Drug Metabolism Clozapine Safety, 40 Years Later
Current Drug Safety Drug Delivery to CNS: Challenges and Opportunities with Emphasis on Biomaterials Based Drug Delivery Strategies
Current Pharmaceutical Design Preparation and Characterization of Bifunctional Nanoparticles of Vitamin E TPGS-emulsified PLGA-PEG-FOL Containing Deferasirox
Nanoscience & Nanotechnology-Asia Modulation of Nitric Oxide Pathway by Multiligands/RAGE Axis: A Crossing Point on the Road to Microvascular Complication in Diabetes
Current Enzyme Inhibition Meaning Centered Psychotherapy: The State of the Art
Current Psychiatry Reviews Alanine Aminotransferase Predicts Outcomes in Elderly Patients with Aneurysmal Subarachnoid Hemorrhage
Current Neurovascular Research The Effect of Counseling on Stress in Infertile Women Admitted to an Infertility Center in Hamadan City, Iran
Current Psychiatry Research and Reviews Targeting SREBP-1-driven Lipid Metabolism to Treat Cancer
Current Pharmaceutical Design Treatment Strategies of Age-Related Memory Dysfunction by Modulation of Neuronal Plasticity
Mini-Reviews in Medicinal Chemistry